BRII-Bに関するコメント

There was HKD1.2 billion and HKD56.9 million Southbound Trading net inflow to $美団点評(03690.HK)$ and $BRII-B(02137.HK)$.
There was HKD3.1 billion, HKD1.9 billion and HKD1.2 billion Southbound Trading net outflow from $TRACKER FUND OF HONG KONG(02800.HK)$, $Hang Seng H-Share Index ETF(02828.HK)$ and $テンセント(00700.HK)$.
For $SH->HK コネクト(GangGuTong.HK)$, $美団点評(03690.HK)$ was the most active stock with highest net inflow of HKD527.1 million,...

$阿里巴巴集団(09988.HK)$ Founder Jack Ma's YF Capital III declared that on 8 July 2022 and 31 January 2023, it reduced its holdings of $BRII-B(02137.HK)$  on market by a total of 8.1595 million shares, cashing in about $87.39 million, according to the Hong Kong Stock Exchange. As such, its shareholding in BRII was trimmed from 7.4% to 5.93%.
YF Capital III is held by Jack Ma and $雲鋒金融(00376.HK)$ 's Chairman ...

$BRII-B(02137.HK)$ should I get in?

$BRII-B(02137.HK)$ is falling??

$BRII-B(02137.HK)$ Great job 👍 Your a winner

$BRII-B(02137.HK)$
I didn't buy it, but I hope it's approved in the US. If the US doesn't ratify it, but we do, frankly, it doesn't mean much. Second, in fact, the market is not too big, there are not many patients. So hopefully the FDA will approve it. That's the real litmus test

$BRII-B(02137.HK)$ On October 9, Tseng Bo announced that it submitted an emergency Use Authorization (EUA) application for novel coronavirus neutralizing antibody Bri-196 / Bri-198 to the FDA today. Tengshengbo has become the fourth pharmaceutical company to submit an APPLICATION for EUA, a novel coronavirus neutralizing antibody, to the FDA, following Genoven, Eli Lilly and Vir Bio. The EUA application is based on positive results from the NIH-supported Phase 3 clinical trial of Activ-2, in which the combination therapy of Bri-196 / Bri-198 resulted in a statistically significant 78% reduction in the risk of hospitalization and death in OUTpatients with COVID-19 who were at high risk of clinical progression to severe disease compared to placebo. And it is safer than placebo.

$BRII-B(02137.HK)$ rose more than 11% to HK $46.95 in intraday trading, hitting a new high with a market value of HK $33.8 billion.
Among 837 patients at high risk of disease progression, the combined endpoint of hospitalization and death was 78% lower than that of placebo, according to a statement issued by Tengsheng Bo on August 25. That means the drug could reduce the death rate among hospitalized patients by 78%. The novel coronavirus neutralizing antibody drug is currently undergoing phase III clinical trials internationally. On September 8, a company official said that the international phase III clinical study of the company's novel coronavirus neutralizing antibody drug has achieved positive results, and the drug is only one step away from approval, which is expected to be approved by the end of this year.